Central adeno id cys tic carcinomas are rare malignan cies tha t are believed to arise in ecto pic salivary gland tiss ue within the maxilta or mandible. We describe the diagnosis and treatment ofa central edenoid cystic carcinoma in a 54-year -old man, which lVe bel ieve lVas a recu rrence ofan earlier growth that had not been cotnp letely excised. We also present a revielV of the literature .
Introduction
Adenoid eys tie earein omas in general are weIl known to otolaryngo logists. Less weIl known are central adeno id eystie ea rei nomas. These tumors are pathologieally identieal to the more co mmon adenoid ey stie eare inomas of the major and minor sa liva ry glands , but they arise fro m within the mand ible or maxilla and ea n extend to the more usual loeat ions. In this report , we deseribe a ease that we believ e rep resent s a reeur rent central ade no id eystie earcmom a,
Case report
A 54-yea r-o ld black man had a 3-m onth history of a slow ly enlarging, painless mass in his parasymphy seal region . Six years earlier, an otolaryngo logis t had removed a lesion that invo lved the mandibul ar gingi va, but the reeords of that reseeti on , spee ifiea lly the path olo gie margins, were not available. The patient had a remote history of toba cco use (one paek of eigare ttes per day for 5 years), and he den ied aIcoho l use. He also deni ed dysp nea, dy sphagia, odynoph agia, and weight loss.
On exa mination, the re was an 8 x IO-em mass fixe d to the mandible in the right parasym physeal region. Th e firm , submueosal lesion extended into the floor of the mouth and abutted the lin gual aspe et of the mandible. After a thorou gh diseussion of the findings, our patient underwent a mod ified radi eal neek disseetion and hem imandibuleetom y as deserib ed later in this repo rt.
Discussion
Adenoid eyst ie earei no ma was origi nally deseribed by Lora in and LabouIb ene in 1853. In 1859, Bill roth eoined the term cylindronia to deserib e the pathologie entity we now eall ad enoid cyst ic carcinoma. Among the first to use the latter term wa s Sp ies in 1930. Until the 1940s, the tum or was thought to be a benign variant of the mixed sali vary gland tumor. In 1943 , Doek ert y and Mayo emphasized the malignant nature of this tum or . For a detailed rev iew of these and other historieal aspeet s of adenoid eystie earein om a, the reader is referr ed to the excellent review by Stell .'
Adenoid eystie ea rei noma is the mo st co mmon minor saIivary gland maIign aney , eomprisin g 42% of all such ca ncers .? It is thou ght to arise from the interea lated duets of mueus-seereti ng glands .' Th e most co mmo n loeation of adenoid eys tie ea rei nom a is the posteri or hard palate, ge nerally in the area of the greater palatine foramen. The tumor dem onstrates a propensity for perineural growth and a high ineidene e of loeal reeurrene e. Less wel Ikno wn, but possibly more imp ortant with regard to bloodborne metastasis, is its proc1ivity for intravaseul ar growth. Longterm followup is esse ntial beeause these tumors are notorious for their late and persistent reeurrenee s. Distant meta stases-most eo mmo nly to the lun g, brain, and bone-oeeur in nearl y 70 % of pati ent s by the time of death. I Togeth er , these eharaete risties aeeount for its ominous pro gn osis.
There are no univ ersaIly agreed-upon pred isposing faetors for the developm ent of adenoid eys tie ea reinoma, AOVERSE REACTlONS Cl inical eff ieaey trials enrolled over 4900 moxilloxaein treated palients. 01 whom over 4300 patients reeeived the400 mgdose. Mostadverse events reported in moxifloxacin trialsweredeseribed asmi ldto moderate in sev er· ityandrequirednoIrealment. Moxi floxacinwas discontinued duetoadverse reaclions though l to be drug-relaled in 3.8% of palienl s. Adverse reaelions, judgedbyinvestigalors10 beal leasi possibl y drug-relal · ed, oceurringin greater than or eQ ualto 1% of moxifl oxaein trealedpalients were: nausea (8%), diarrhea (6%), dizziness (3%), headaehe(2%), abdom· inal pain (2%), vomi ting (2%), taste perversion (1%), abnormalliverfunclion test(1%), and dyspepsia (1%). Addilional evenls, judgedbyinvesligalors10 bealleasi possi bly drug-relat · ed, that oeeurred in greater than0.05% and less than 1% of moxifloxaein treated palienls were: BODYASAWHOLE: aslhenia, moniliasis, pai n, mal aise, labtest abnormal (noi speeifled InformalionforPati ents:
To assuresale and effective use 01 moxifloxacin, Ihe follovJi nginlormalion and instruelionsshould beeommunicated toIhepatent when appropriate: Pat ients shou ld beadvised: -that moxilloxacin may produce changes in the eleetrocardiogram (OTc interval prolongat ion). -t nat rnoxlüoxacln snoulo be avoiced in pauents receiving Class lA (e.g. quinidine, procainamide) Dr Class III(e. g. amiodarone, sotalol) antiarrhyt hmi eagents. • Ihal moxifloxaeinmayadd10theOTeprolongingetteetsof othe r drugssuch ascisapride. erythromyein,antipsycholics, and tricyelieantidepressants. -10 inform theirphysician of any personal or familyhi story of OTe prolongationorproarrhythmiecondltionssuch asreeent hypokalemia, significant bradycar dia, aeutemyocardi al ischernia. -to informtheirphvsician of anyother medicationswhen taken coneurrently with moxifl oxaein, includingever-me-counter medieations. • to eonlaet theirphysicianif they experience pal pitati ons or faintingspells whiletaking moxi floxacin. -thatmoxifloxaein may be takenwith or without meal s, and to drink üui ds liberally. -thatmoxi floxaein should betaken at least 4 hours before or 8 hours aner multivi tamins (containingironorzine),antaeds(containi ngrnaqnesium, ealeium, Dralumirurn), sucraltate, Dr Vide X" (didanosine) ehewable!buffered labietsDrIhepedialrie powcer lor oral soi unori (SeeCLlNICAL PHARMA-COLOGY, Orug Inleraelions and PRECAUTlONS, Orug Inleraelions.) -that moxilloxaein may beassociated wilh hypersensitivity reactions, even following a singl e cose, and to diseonlinue thedrug al the firsl signof a ski n rash or other signsofanallergie reacnon, • to discontinuetreat ment; rest and relrainfrom exercise; and intarm their physieianif they experience pai n. inflammalion, orruptureof a tendon. • that moxifloxaeinmaycause di llinessandlighlheadedness; therefore, pat ients shouldknowhowIheyrea el lothi sdrug beforeIheyoperateanaulomobile Dr machineryor engage inactiviliesrequiringmenlal alertness oreoordination. • that phot oloxicity has been reported in patient s reeeiving certain Q uino! ones. Therewas no phot otoxicityseen with moxifloxaei n at Ihe ree· ommended dose. In keepingwith good me dical practice, avoid excessi ve sunl ighl Drarti fieial ullraviolel Iighl (e.g.Ianningbeds Pharmaeokinetiestudiesbetv'l' een moxifloxaeinand other drugs that prolong IheOTinlerval such ascisapride, eryt hromyein. anlipsyehoties, andlrieyelie antidepressants havenot been performed. Anadd itive effeet of moxlfloxaein and these drugs cannol beexeluded, Iher efore moxiflox aei n should beused withcaution when given eoneurrentlywith thesedrugs. Theeffeet of moxifloxaein on pal ienls wilh eongenilal prol ongalionof theaT intervalhas not beenstudied, however, it is expeeted thatthese individuals may bemoresuseeplible10 drug-indueed aT prolongalion. Beeause of Iimitedcli nicalexperience, moxifloxaei n shouldbeused wilh eaulion in patienl s wilh ongo ingproarrhythmie eondilions, such aselinieally signifieant bradycardia, aeutemyocardial isel1emia. Themagnitude ofaTprol ongationmay inerease wilhinereasingeoncentrations of Ihedrug,Ihereforethereeommended dose shouldnoi beexeeeded.aTprolongal ionmay leadtoaninereased riskforvenlrieulararrhythmiasineludingtor· sade depoi nles. In 787palienls wilh pai red valid ECGs inPhase IIIelinica l lrials , Ihemean ;t SOeHeet 01moxi lloxaein 400 mgonIhe OTeinl erval was 6 ;t 26mse e. No cardiovaseular morbidity Drmortality attribulable10 OTe prolongationoccurredwilhmoxill oxaeintreat ment inover4000paUents, howevereer· tainpredi sposi ng eondilionsmay inereasetherisk forventrieular arrhyt hmias. Th e oral administrat ion 01 mox ifloxaein caused lameness in immature dogs. Hi slopalhol ogical examinationof Iheweighl-bearingjoints ofIhesedogs revealed permanent lesi ons of the cartHage. Relatedqui nolone-elass drugs also produce erosions of cartilage of weighl-bea ring joinlsandol hersigns of art hropalhy in imma tureani mals of variousspecies. (See ANIMAL PHARMACOLOGY.) Convulsions have been repo rted in patients reeeiving quinolones. Oulnol ones may also cause central nervous system (CNS) eve nlsineluding: diuiness, eonfusion,tremors, hallueinations, depr ession, and, rarely, suicidal Ihoughls Dr aels. These reaclions may oeeur following thefirsl dose. If Ihese reaetions oeeur in pat ients reeeiving moxifJoxaein, thedrug shouldbe diseonlinued and appropr iate measures inst iluled. As with all quinolones, moxifloxaein should be used with cautionin patients wilh known or suspeel ed CNS disorders (e.g. sev ere eerebral arterioselerosis, epilepsy) Dr in thepresenee of otherriskfaelors that may predispose to seizures or lower Ihe seizure Ihreshoid. (See PRECAUTlONS: General, Inlormalion lor Palienls, and AOVERSE REACTIONS.) Serious and oecasionally falal hypersensitivity (anaphylaelie) reaelions, some following the first dose, have been reported in patients reeei ving quinolone therapy. Some reaetions were aeeompanied by car diovaseular eollapse, loss of eonseiousness, lingling, pharyngeal Drfaeial edema, dyspnea, urti earia, and itehing. Seriousanaphylae ticreactions requireimmediate emergencytreatment withepinephrine. Moxifloxacin sho uldbediseontinued at thefirsl appearanee of a skin rash or any othersign of hypersensitivity. Oxygen, intravenous steroids, andairway management,includingintubat ion, may beadministered asindiealed. Severeand sometimes fatal events, some dueto hypersensit ivity, and some 01uncertain eliology,havebeen reported inpati ents reeeiving therapywith all anlibiot ics. These events may be severe and generally oceur loll owing the administral ion of multipl e doses. Clinical manifestati ons may inelude one or mare of thefollowing: rash, lever, eosinophilia, jaundice,and hepatieneerosis. Pseudom embranous eolilis !la sbeen reporled with nearlyall antibaeterial agenls and may rang e in severity from mild to life-threatening. Therefore, il is imporlant to eonsider this diagnosis inpatientswhopresenl wilhdiarrheasU bsequent to theadministralian 01 antibaclerial agenls.
Treatmentwith antibaeterial agents alters the normaii iara of the eolon and may permi t overgrowth of elostridia. Sludiesindieatethata toxin produeed by Clostridium difficile isoneprimarvcause of "antibiotic-associated eolitis." After the diagnosis of pseudomembranou.s eol itis has been established, Iherapeutic measures should beinit iated. Mlld casesofpseudomembrano us eolitisusually respondto drug discontinuationalone. In moderate to seve re cases , eonsiderat ion should be gi ven to managemenl with fluids and e l ecl rolytes, prot ein supplementation, and treatment with ananlibaeterialdrug elinically effeetiveagainstC. and the re seems to be no famiii al ten den ey. Ther e is a very slig ht fe ma le prep onde ra nee. Pat ie nts typieally present w ith a slowly enlargi ng mass tha t, beeau se of its indo lent growth patt ern , ean be quite lar ge . T he mass is usu all y painl ess, altho ug h bon e in vasion o r per ineural sprea d ea n ea use pain or hyp oesth esia. Most ade noid eystie carc inomas are sub mueos al and app ea r as srnooth, domed swellings w itho ut o verl ying ulc er ati on. Th ey are un en eap sulated but frequently weil eire umse ribed ; thi s appearanee is mi sleading beeause th ese lesion s have an insidiou sly in filtrative growth pattern. Th e inc ide nee of eer vieal Iymphatic met asta sis is low: abo ut 8 % at presentati on and 7% later.' Hist ol ogi cally, ther e are th ree reeogni zabl e patt erns of g rowth, representing a spee trum of ex tre mes of differ entiati on: so lid, er ibriform , a nd tu bul odu etal. Th e so lidg rowth arch itecture port ends an ex tre me ly poor pro gn osis in ade no id eystie ea rc ino ma. It is the exceptio n to th e indo len t growth patt ern a nd usu all y dem on st rates a highl y aggressive e1inical co urse, with early an d more frequent recu rrence (nearly 100 %), met ast asis, and death wit hin 3 to 4 years o f d iagn osis. O n the ot her e nd of th e spectru m is the tubul oduet al arc hi tec ture, which is associated wi th th e mor e-typ ical ind ole nt growth rate an d th e lo west ra te of reeurrence at 59%. Between these ex tre mes lies the most co m mo n patt ern , th e er ib rifo rm architec ture , whic h is associate d with a reeurren ee rate of 89 %.4Bat sak is et al have pro posed a gra di ng syste m th at eon sid er s cy toarchitecture as weil as perin eural invasion , mit oti e rat e, stromai cha nges, neerosis, and the degr ee to which th e border is well-c ircumscribed.' CT and magnetic resonance im aging are useful in surg ica l planning, es pecially wi th regard to the subm ueosal ex te nt and perineural spread, w hic h ea n be difficult to assess e1inicall y. Th e lesion s are ge nerally po orl y defined a nd have infiltrati ve margins. Th e ce nter of th e lesion , as was the ease w ith o ur pat ient, is usu all y lo wde ns ity o n CT , a eharaeter istie th at ca n hel p differenti ate it fro m a prim ary squa mo us ee li ca rc ino rna.?
T he tum or in our pat ient had its radi ograph ie epicenter wit hin the bo ne of th e mandible . T his ge nerated a discu ssio n among the autho rs as to whe ther or not it rep resented a pr im ar y ce ntral bon y adenoi d cystic ea rci no ma of the mandi ble .
Eetopi e sa liv ary gla nd tissu e has been obse rve d in several head and neek locati on s, including the eervical skin, middle ea r, mastoid , m axill a, and mandible. A Ith ou gh rare, salivary gland malign an cies ca n ari se in such ee to pic salivary gland tissu e. Brook stone and Huvos re view ed th e re levant liter ature and fou nd 137 such cases arising in the ma xi lla and mandible ; ade no id ey stie earcinoma w as the seco nd most co mmo n histologie subtype (23 ca ses), foll o win g mu coep iderm oid carei no m a (8 1 cases).' They found that swelling a nd pain we re th e two most co m mo n presenting eom pla int s fo r ce ntral salivary gla nd tumor s involvi ng the j a ws. Thirty pereent of th ese cases arose in associatio n wi th an odontogenie cyst or a recent histo ry of tooth ex tractio n. The pathogen esi s of these tum ors is co ntrove rs ial , bu t severa l autho rs have prop osed that th ey involve a met apl ast ic tran sformatio n of th e mu cu s-seereting ce lls common ly found in the epi the lia l lin ings of de ntigerous cysts an d odo ntogenic epi the liurn." ? Primar y ce ntral ade no id cystic earcino mas ha ve a sig nifieantly high er rate of met astasis th an do mu coepiderm oid earei no ma s (50 and 9 %, res pective ly) .?
Th e treatment of ad en oid eysti c ca rc ino ma invol ves sur gieal reseet ion w ith w ide mar gin s. The surgeo n mu st pay particul ar atte ntio n to obtaining e1ear margin s aro und regi on al nerves. The surgi ea l ablation mu st be ind ividualize d becau se rad ica lly mutil atin g surgery doe s not ap- pear to improve the prognosis in highly agg ressive tumors. Neck dissection should be perform ed in those patient s who have clinic al or radiolo gic evidence of cervical lymphatic meta stasis. Proph ylactic neck dissection is generally not recomrnended .? Postop erativ e radiation therapy enhances local and regional control in adenoid cys tic carcinom a. Radical surgery follow ed by postoperative radiation therapy result s in 5-and l O-year survival rates of 77 and 57 %, respectively.'" Ult imately , we determined that the mass in our patient was a prim ary centr al adenoid cystic carcinoma and that the patient' s pre vious surge ry was an incomplete local excision of a presum ed gingival adenoid cystic carcinoma. Our conclusion was supported by the growth pattern on C'I', Our patient underwent a modi fied radical neck dissection and hemimandibulectomy, including reconstruction with a free fibula graft, which provided an excellent funct ional and cos metic result. Th e margins were free of disease, and only the one clin ically positiv e neck node was path ologi cally positive. Postoperative radi ation therapy was administered to the primary site and to the ipsilatera l neck . The patient is free of disea se at 4.5 years followup.
Thi s case illu strates two key fact s regard ing the diagnosis and treatment of adenoid cystic carcinoma. First, central salivary gland tumo rs should be con sider ed in the differential dia gno sis of aggres sive lesions in the maxilla and mandibl e. Second , long-te rrn followup is essent ial regardless of the site becau se of the turnor' s propensity for late recurrence and metastasis.
